Inovio's First Approval Shifts the Question From Regulators to Revenue

Inovio Pharmaceuticals now has something it has never had before: a product cleared for sale. The accelerated FDA approval granted on Friday covers VOCERYQ, formerly INO-3107, a treatment intended to cut the frequency of surgeries in adults with recurrent respiratory papillomatosis (RRP). It is the company's first approved product — and the event that changes how the stock must be judged.

The shift is not a clean handover from development to sales. Because the accelerated clearance is tied to a confirmatory study, regulatory work and commercial build-out are running at the same time rather than one after the other. The FDA wants a draft protocol by the end of 2026, with final agreement expected by mid-2027. Until clinical benefit is confirmed, the approval's durability rests on data still to come.

Two Timetables, One Company

Management expects orders and shipments to begin roughly 60 days after the approval notice. A full commercial launch is planned for the first quarter of 2027. Those are expectations and plans, not distribution already under way.

The near-term calendar adds a financial checkpoint. Inovio said yesterday it will report third-quarter 2026 results on November 10 after the market close, followed by a conference call and webcast. That report will be the first hard look at the balance sheet behind the launch.

Funding is the tight spot. The company's projected cash runway extends into late in the first quarter of 2027 — the same window in which the broad launch is supposed to happen. A court award is not the same as cash in hand: on October 20 a US court awarded Inovio a total of $80.4 million against VGXI and GeneOne, but collection is uncertain given the defendants' financial position.

What the Buy Call Actually Assumes

H.C. Wainwright upgraded the shares from Neutral to Buy yesterday and lifted its price target to $5.00, according to media reports. The upgrade followed the approval.

The model rests on more than the regulatory green light. The brokerage projects a peak annual sales figure of $450 million for VOCERYQ, assigns the company an enterprise value of $670 million, and assumes 133.5 million shares outstanding by the end of 2027. Those are modelling inputs, not achieved results — and they carry two distinct bets: that VOCERYQ can open a commercial market, and that the valuation will be spread across a larger future share count. A large revenue opportunity alone does not settle what each share is worth.

Wainwright also raised the approval probability in its model from 75% to 100%, which removes the regulatory risk it had previously priced in. That adjustment does not erase the remaining clinical and commercial risks, and a sales forecast is not evidence of actual demand.

A Weak Tape Beside a Stronger Rating

The more positive analyst view and a soft trading session can sit side by side without one explaining the other. That juxtaposition is not proof of any particular cause for the share price move.

For investors, the more useful test is not which of those two snapshots sounds more convincing. It is how Inovio funds the transition to a product business and executes it operationally. The November 10 report is the next concrete date on which that can be measured.